Graham Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Graham Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$429K	Buy	+19,615	New	+$408K	0.01%	760
2025 Q1	–	Sell	-52,790	Closed	-$698K	–	1499
2024 Q4	$698K	Sell	52,790 -5,149	-9%	-$88.1K	0.01%	602
2024 Q3	$1.12M	Sell	57,939 -17,712	-23%	-$366K	0.02%	426
2024 Q2	$1.55M	Sell	75,651 -4,535	-6%	-$94.9K	0.03%	302
2024 Q1	$1.91M	Buy	80,186 +65,250	+437%	+$1.46M	0.04%	260
2023 Q4	$323K	Buy	+14,936	New	+$230K	0.01%	704

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Graham Capital Management's SNDX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 19,615 shares worth $429K. The stake represents 0.01% of the portfolio and ranks #760 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in SNDX as recently as Q4 2024.

Graham Capital Management first reported a position in SNDX in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.91M in Q1 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Graham Capital Management held 19,615 shares of Syndax Pharmaceuticals worth $429K as of Q2 2026.
Syndax Pharmaceuticals was a new Graham Capital Management position in Q2 2026.
Syndax Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #760 holding.
Graham Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
Graham Capital Management's Syndax Pharmaceuticals position peaked at $1.91M in Q1 2024.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.